Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Kennedy, Jae
Tien, Yu Yu
Cohen, Lawrence J.
Sclar, David Alexander
Liu, Darren
Blodgett, Elizabeth G.
and
Engle, Josh
2009.
The association between class of antipsychotic and rates of hospitalization: Results of a retrospective analysis of data from the 2005 medicare current beneficiary survey.
Clinical Therapeutics,
Vol. 31,
Issue. 12,
p.
2931.
Kane, John M.
and
Correll, Christoph U.
2010.
Pharmacologic treatment of schizophrenia.
Dialogues in Clinical Neuroscience,
Vol. 12,
Issue. 3,
p.
345.
Beninger, Richard J.
Baker, Tyson W.
Florczynski, Matthew M.
and
Banasikowski, Tomek J.
2010.
Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients.
Neurotoxicity Research,
Vol. 18,
Issue. 3-4,
p.
229.
Citrome, L.
2010.
Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic.
International Journal of Clinical Practice,
Vol. 64,
Issue. 6,
p.
707.
Rummel-Kluge, Christine
Komossa, Katja
Schwarz, Sandra
Hunger, Heike
Schmid, Franziska
Lobos, Claudia Asenjo
Kissling, Werner
Davis, John M.
and
Leucht, Stefan
2010.
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis.
Schizophrenia Research,
Vol. 123,
Issue. 2-3,
p.
225.
Leucht, Stephan
Correll, Christoph U.
and
Kane, John M.
2010.
Schizophrenia.
p.
540.
2010.
The Use and Misuse of Psychiatric Drugs.
p.
165.
Mattai, Anand K
Hill, Julia L
and
Lenroot, Rhoshel K
2010.
Treatment of early-onset schizophrenia.
Current Opinion in Psychiatry,
Vol. 23,
Issue. 4,
p.
304.
Semenova, Svetlana
and
Markou, Athina
2010.
The α2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats.
European Neuropsychopharmacology,
Vol. 20,
Issue. 10,
p.
731.
Kim, Sung‐Wan
Yoo, Joon‐An
Lee, Sam‐Yeon
Kim, Seon‐Young
Bae, Kyung‐Yeol
Yang, Su‐Jin
Kim, Jae‐Min
Shin, Il‐Seon
and
Yoon, Jin‐Sang
2010.
Risperidone versus olanzapine for the treatment of delirium.
Human Psychopharmacology: Clinical and Experimental,
Vol. 25,
Issue. 4,
p.
298.
Terry, Alvin V.
Gearhart, Debra A.
Pillai, Anilkumar
Zhang, Guodong
and
Bartlett, Michael G.
2010.
Chronic antipsychotic treatment: protracted decreases in phospho-TrkA levels in the rat hippocampus.
The International Journal of Neuropsychopharmacology,
Vol. 13,
Issue. 06,
p.
799.
Centorrino, Franca
Ventriglio, Antonio
Vincenti, Alessio
Talamo, Alessandra
and
Baldessarini, Ross J.
2010.
Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004.
Human Psychopharmacology: Clinical and Experimental,
Vol. 25,
Issue. 2,
p.
179.
Hasan, Alkomiet
Wobrock, Thomas
Reich-Erkelenz, Daniela
and
Falkai, Peter
2011.
Treatment of first-episode schizophrenia: pharmacological and neurobiological aspects.
Drug Discovery Today: Therapeutic Strategies,
Vol. 8,
Issue. 1-2,
p.
31.
Ibrahim, Hisham M.
and
Tamminga, Carol A.
2011.
Schizophrenia: Treatment Targets Beyond Monoamine Systems.
Annual Review of Pharmacology and Toxicology,
Vol. 51,
Issue. 1,
p.
189.
Kendall, Tim
2011.
The rise and fall of the atypical antipsychotics.
British Journal of Psychiatry,
Vol. 199,
Issue. 4,
p.
266.
Greenblatt, David J.
Harmatz, Jerold S.
and
Shader, Richard I.
2011.
Psychotropic Drug Prescribing in the United States.
Journal of Clinical Psychopharmacology,
Vol. 31,
Issue. 1,
p.
1.
Schwenger, Erin
Dumontet, Jane
and
Ensom, Mary H.H.
2011.
Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?.
Clinical Pharmacokinetics,
Vol. 50,
Issue. 7,
p.
415.
Parabiaghi, Alberto
D'Avanzo, Barbara
Tettamanti, Mauro
and
Barbato, Angelo
2011.
The GiSAS study: Rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia.
Contemporary Clinical Trials,
Vol. 32,
Issue. 5,
p.
675.
Bernardo, Miquel
Vieta, Eduard
Saiz Ruiz, Jerónimo
Rico-Villademoros, Fernando
Álamo, Cecilio
and
Bobes, Julio
2011.
Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry.
Revista de Psiquiatría y Salud Mental (English Edition),
Vol. 4,
Issue. 3,
p.
150.
Barnes, Thomas RE
2011.
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology.
Journal of Psychopharmacology,
Vol. 25,
Issue. 5,
p.
567.